Oral Niacinamide: Skin Barrier, Anti-Aging, and Ro…

Niacinamide—the amide form of vitamin B3 (niacin)—has become one of the most celebrated topical skincare ingredients of the past decade, with evidence for reducing hyperpigmentation, strengthening the skin barrier, reducing sebum, and calming inflammation. But oral niacinamide, while less discussed in skincare circles, has its own substantial evidence base in dermatology—including a landmark trial showing it reduces skin cancer incidence and multiple studies on its effects on the skin barrier, rosacea, and photo-aging.

Mechanisms of Action

Niacinamide's skin effects are driven by its role as a precursor to NAD+ (nicotinamide adenine dinucleotide)—the central energy currency of every cell. NAD+ is required for DNA repair, cellular energy production, and the activity of sirtuins (proteins that regulate cellular aging). UV radiation depletes cellular NAD+ by activating PARP-1 (a DNA repair enzyme that consumes NAD+). Supplementing niacinamide replenishes NAD+, restoring DNA repair capacity and protecting against UV-induced cellular damage. Additionally, niacinamide inhibits the transfer of melanosomes from melanocytes to keratinocytes (reducing pigmentation), stimulates ceramide synthesis in the skin barrier, and suppresses inflammatory pathways relevant to rosacea and acne.

Skin Barrier Strengthening

Niacinamide stimulates the synthesis of ceramides, free fatty acids, and cholesterol—the three major lipid components of the stratum corneum that determine barrier integrity. A well-structured lipid barrier reduces transepidermal water loss (TEWL), prevents irritant and allergen penetration, and reduces the chronic low-grade inflammation that drives accelerated skin aging. Studies on topical niacinamide demonstrate clear barrier-improving effects; oral niacinamide works through the same NAD+-dependent pathways in keratinocytes to support the metabolic processes that build this barrier. In people with eczema, rosacea, or chronically dry and sensitive skin, oral niacinamide at 500 mg twice daily supports barrier restoration alongside topical treatment.

The ONTRAC Trial: Skin Cancer Prevention

The most significant clinical trial involving oral niacinamide for skin is the 2015 ONTRAC (Oral Nicotinamide to Reduce Actinic Cancer) study—a randomized, double-blind, placebo-controlled trial of 386 high-risk patients (those with two or more previous non-melanoma skin cancers). Nicotinamide at 500 mg twice daily (1,000 mg/day total) reduced new squamous cell carcinoma and basal cell carcinoma incidence by 23% compared to placebo over 12 months. The mechanism: niacinamide replenishes UV-depleted NAD+, restoring DNA repair capacity in sun-damaged keratinocytes. This is now recommended by some dermatologists as an adjunct for high-UV-exposure individuals and those with a history of actinic keratoses or skin cancer.

Rosacea

Rosacea is driven by a combination of neurovascular reactivity, dysbiosis of the skin microbiome (particularly Demodex mites and S. epidermidis), and inflammatory cytokine overproduction. Oral niacinamide at 750 mg/day has been studied in combination with other nutrients for rosacea and shown improvements in facial redness and inflammatory papule counts. Niacinamide's anti-inflammatory mechanism—reducing IL-1beta, TNF-alpha, and NF-kB activation in keratinocytes—directly addresses the inflammatory component. It also supports the ceramide-rich barrier that rosacea skin characteristically lacks, reducing triggering from environmental stressors.

Anti-Aging and Wrinkle Reduction

By replenishing NAD+ and supporting sirtuin activity, oral niacinamide contributes to cellular aging pathways relevant to skin quality. Sirtuins regulate collagen gene expression, inflammatory signaling, and epigenetic maintenance in dermal fibroblasts. Higher NAD+ availability—supported by niacinamide supplementation—allows sirtuins to maintain more youthful fibroblast function. Studies using related NAD+ precursors (NMN and NR) have shown improvements in skin hydration, elasticity, and wrinkle depth in RCTs; niacinamide as a simpler and more cost-effective NAD+ precursor likely confers similar benefits, though direct comparative trials are limited.

Dosing and Safety

For skin cancer prevention: 500 mg twice daily (1,000 mg/day), as studied in ONTRAC. For barrier support, rosacea, and anti-aging: 500 mg/day is a common clinical recommendation. Niacinamide is distinct from nicotinic acid (niacin)—it does not cause the flushing reaction associated with niacin. It is generally very well tolerated up to 3,000 mg/day. High doses above 3,000 mg/day have been associated with rare liver enzyme elevation. Standard skin health doses (500–1,000 mg/day) are well within the safety window.

FAQ

Is oral niacinamide better than topical for skin? Both have evidence and work through overlapping but not identical mechanisms. Topical niacinamide directly inhibits melanosome transfer (reducing dark spots) and strengthens the surface barrier. Oral niacinamide replenishes NAD+ systemically and has cancer-prevention evidence that topical cannot achieve. Using both is a comprehensive approach.

Can oral niacinamide cause flushing like niacin? No. Niacinamide (nicotinamide) does not cause the prostaglandin-mediated flush associated with nicotinic acid (niacin). They are different forms of vitamin B3 with different pharmacological profiles.

How long before oral niacinamide improves skin barrier function? Barrier improvements from oral niacinamide take 4–8 weeks to manifest as reduced sensitivity and improved hydration retention. Effects on pigmentation and anti-aging develop more slowly, typically at 12–16 weeks.

Track your supplements in Optimize.

Oral Niacinamide: Skin Barrier, Anti-Aging, and Rosacea Evidence